TrialJournal of Crohn's & colitis2018

A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease.

Stefan Schreiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.